The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease

Curr Pharm Des. 2012;18(8):1123-30. doi: 10.2174/138161212799315795.

Abstract

The senescence accelerate mouse P8 (SAMP8) is an excellent model of early learning and memory problems. A number of studies have shown that it has cholinergic deficits, oxidative damage, alterations in membrane lipids and circadian rhythm disturbances. The brains of the SAMP8 overproduce amyloid precursor protein (APP), amyloid-beta protein and have an increased physphorylation of tau. An antisense to APP has been developed that reverses the cognitive deficits and oxidative damage. This antisense represents a potential treatment for Alzheimer's disease.

Publication types

  • Review

MeSH terms

  • Aging
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / physiopathology*
  • Amyloid beta-Peptides / metabolism
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Brain / physiopathology
  • Circadian Rhythm
  • Cognition Disorders / drug therapy
  • Cognition Disorders / etiology
  • Disease Models, Animal*
  • Drug Design
  • Humans
  • Membrane Lipids / metabolism
  • Mice
  • Oligonucleotides, Antisense / pharmacology*
  • Oxidative Stress / drug effects

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Membrane Lipids
  • Oligonucleotides, Antisense